Research Analysts Issue Forecasts for GANX Q3 Earnings

Gain Therapeutics, Inc. (NASDAQ:GANX) – Equities researchers at Roth Capital lifted their Q3 2025 earnings per share (EPS) estimates for shares of Gain Therapeutics in a report issued on Tuesday, August 12th. Roth Capital analyst B. Pachaiyappan now expects that the company will earn ($0.16) per share for the quarter, up from their prior forecast of ($0.18). Roth Capital currently has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for Gain Therapeutics’ current full-year earnings is ($1.00) per share. Roth Capital also issued estimates for Gain Therapeutics’ Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.69) EPS, Q1 2026 earnings at ($0.16) EPS, Q2 2026 earnings at ($0.19) EPS, Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.24) EPS and FY2026 earnings at ($0.81) EPS.

Gain Therapeutics (NASDAQ:GANX) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.02).

Separately, HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of Gain Therapeutics in a research report on Thursday, July 3rd. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $7.80.

Gain Therapeutics Stock Performance

GANX stock opened at $1.73 on Friday. The company has a current ratio of 1.79, a quick ratio of 2.22 and a debt-to-equity ratio of 0.09. The firm has a market cap of $62.19 million, a P/E ratio of -2.75 and a beta of 0.10. Gain Therapeutics has a 12-month low of $0.95 and a 12-month high of $3.19. The stock’s 50 day simple moving average is $1.68 and its 200 day simple moving average is $1.90.

Institutional Investors Weigh In On Gain Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in GANX. Marshall Wace LLP increased its position in Gain Therapeutics by 41.0% in the second quarter. Marshall Wace LLP now owns 276,433 shares of the company’s stock worth $498,000 after buying an additional 80,407 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Gain Therapeutics by 2.9% during the second quarter. Geode Capital Management LLC now owns 290,462 shares of the company’s stock valued at $523,000 after acquiring an additional 8,251 shares during the period. Kovitz Investment Group Partners LLC bought a new position in shares of Gain Therapeutics during the first quarter worth about $91,000. Dauntless Investment Group LLC bought a new position in shares of Gain Therapeutics during the first quarter worth about $240,000. Finally, Bridgeway Capital Management LLC acquired a new stake in shares of Gain Therapeutics in the 4th quarter worth about $65,000. 11.97% of the stock is owned by institutional investors and hedge funds.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.